A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, Ipsc-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma
Blood（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined